Progress of immunotherapy of acute myelogenous leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 12-16, 2019.
Article
in Zh
| WPRIM
| ID: wpr-732677
Responsible library:
WPRO
ABSTRACT
Acute myelogenous leukemia (AML) is a highly heterogeneous malignant hematologic disease, and its clinical treatment mainly includes traditional chemotherapy, but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy. In recent years, immunotherapy has achieved certain curative effects in AML which shows a promising prospect. This review introduces immunotherapy of AML reported in 60th American Society of Hematology (ASH) Annual Meeting.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Leukemia & Lymphoma
Year:
2019
Type:
Article